ANALYST-UPGRADE filed
Piper Sandler initiated coverage on Thermo Fisher Scientific at Neutral with a $510 price target, implying a modest 5.8% upside from the current $482.04. The firm's 54% accuracy on 3,763 calls and average 3.6% return position it near the middle of analysts covering TMO. The broader consensus remains heavily bullish: 29 of 34 analysts rate the stock Buy (85%), with only 5 Holds and zero Sells. The mean price target is $602.76 (25% upside), while Piper's $510 sits just above the consensus low of $490. EPS revisions over the past 30 days are mixed, current-quarter estimates saw 12 downward revisions vs. 2 upward, but next-quarter estimates improved 14 up vs. 3 down. Insider activity is limited: one small sale in late April and two small Congressional trades (one buy, one sell). Institutional flows show a major add by Capital Research (+51.5%) and a new position from Renaissance Technologies, offset by significant trims from Wellington and Capital World. Short interest is elevated at a 62% ratio, suggesting bearish positioning. Overall, Piper's cautious initiation contrasts with the bullish street view, but given its average track record, the call carries limited catalyst weight unless earnings on July 21 surprise.